Table 1.
Clinicoepidemological characteristics of individuals with a history of SARS-CoV-2 natural infection and/or COVID-19 vaccination.
| NI (n = 125) | VX (n = 129) | |||||
|---|---|---|---|---|---|---|
| De-Identifieda | n = | 44 | (35%) | ––– | ||
| NI (n = 81) | VX (n = 129) | |||||
| Gender | ||||||
| Male | n = | 35 | (43%) | n = | 54 | (42%) |
| Female | n = | 46 | (57%) | n = | 75 | (58%) |
| Age in years | ||||||
| Mean ± SD (range) | 47.35 ± 15.78 (20 - 83) | 44.86 ± 19.45 (20 - 85) | ||||
| Median (IQR) | 48.00 (34.50 - 59.25) | 40.00 (27.00 - 60.00) | ||||
| Days Post Symptom Onsetb | ||||||
| n = | 67 | (83%) | ––– | |||
| Mean ± SD (range) | 122.51 ± 125.24 (13 - 558) | ––– | ||||
| Median (IQR) | 75.00 (24.00 - 175.50) | ––– | ||||
| Days Post SARS-CoV-2 PCR Positivityb | ||||||
| n = | 64 | (79%) | ––– | |||
| Mean ± SD (range) | 93.09 ± 84.43 (11 - 348) | ––– | ||||
| Median (IQR) | 53.50 (22.00 - 150.75) | ––– | ||||
| COVID-19 Vaccination with and without History of Natural Infection | ||||||
| n = | 42 | (52%) | n = | 129 | (100%) | |
| Pfizer-BioNTech | n = | 28 | (67%) | n = | 66 | (51%) |
| Moderna | n = | 12 | (29%) | n = | 59 | (46%) |
| J&J/Janssen | n = | 2 | (5%) | n = | 3 | (2%) |
| Days Post COVID-19 Vaccination | ||||||
| No. Samples | n = | 61 | n = | 271 | ||
| Dose 1 (≥ 10 and ≤ 42 days) | n = | 20 | (33%) | n = | 56 | (21%) |
| Mean ± SD (range) | 18.60 ± 8.45 (10 - 39) | 19.61 ± 6.07 (13 - 41) | ||||
| Median (IQR) | 15.50 (14.00 - 21.00) | 19.00 (14.00 - 23.25) | ||||
| Dose 2c (≥ 10 days) | n = | 41 | (67%) | n = | 199 | (73%) |
| Mean ± SD (range) | 41.88 ± 42.28 (10 - 212) | 87.96 ± 81.87 (10 -323) | ||||
| Median (IQR) | 26.00 (16.00 - 48.00) | 47.00 (19.00 - 145.00) | ||||
| Dose 3 (≥ 10 days) | n = | 0 | (0%) | n = | 16 | (6%) |
| Mean ± SD (range) | ––– | 32.13 ± 31.05 (13 - 135) | ||||
| Median (IQR) | ––– | 20.00 (17.00 - 28.00) | ||||
NI = history of SARS-CoV-2 natural infection; VX = COVID-19 vaccination without a history of SARS-CoV-2 natural infection; SD = standard deviation; IQR = interquartile range. aDe-identified/anonymized medical waste with clinical history of SARS-CoV-2 natural infection, with no associated clinicoepidemiological data were available. bVaried reporting for days post symptom onset and days post PCR positivity due to asymptomatic infection, and lack of access to SARS-CoV-2 testing. cDose 2 = complete COVID-19 vaccinaton, two doses of a Pfizer-BioNTech or Moderna COVID-19 vaccine or one dose of J&J/Janssen COVID-10 vaccine.